Amble vs MEDVi
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Amble
Best for mainstream telehealth GLP-1 accessStarting at $179/mo
MEDVi
Best for mainstream telehealth GLP-1 accessStarting at $179/mo
Side-by-Side Comparison
| Feature | Amble | MEDVi |
|---|---|---|
| Overall Score | ✓7.4/10 | 7.2/10 |
| Starting Price | $179/mo | $179/mo |
| Editorial Rating | ✓3.7 ★ /5 | 3.6 ★ /5 |
| Features | 3 features | 3 features |
| States Available | ✓50 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Amble
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
MEDVi
Pros
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
Cons
- ✗Limited public information on program details
Our Verdict
Amble edges out MEDVi with a higher overall score of 7.4/10 and is particularly strong for mainstream telehealth GLP-1 access. MEDVi remains a solid alternative, especially if you're looking for mainstream telehealth GLP-1 access.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.